Clearmind Financial Statements From 2010 to 2025

CMND Stock  USD 1.38  0.01  0.73%   
Clearmind Medicine financial statements provide useful quarterly and yearly information to potential Clearmind Medicine Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Clearmind Medicine financial statements helps investors assess Clearmind Medicine's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Clearmind Medicine's valuation are summarized below:
Market Capitalization
6.3 M
Earnings Share
(1.69)
There are over one hundred nineteen available fundamental signals for Clearmind Medicine Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Clearmind Medicine's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 5.6 M, whereas Enterprise Value is projected to grow to (506.2 K).
Check Clearmind Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearmind Medicine's main balance sheet or income statement drivers, such as Interest Expense of 70.6 K, Selling General Administrative of 2.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.8. Clearmind financial statements analysis is a perfect complement when working with Clearmind Medicine Valuation or Volatility modules.
  
Check out the analysis of Clearmind Medicine Correlation against competitors.

Clearmind Medicine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8.8 M8.3 M2.4 M
Slightly volatile
Total Current LiabilitiesM4.8 M1.4 M
Slightly volatile
Accounts Payable635.2 K605 K235.7 K
Slightly volatile
Cash7.9 M7.6 MM
Slightly volatile
Other Current Assets95.4 K50.8 K49.6 K
Slightly volatile
Total LiabilitiesM4.8 M1.4 M
Slightly volatile
Short and Long Term Debt24.9 K35.7 K28.3 K
Slightly volatile
Total Current Assets8.6 M8.2 M2.2 M
Slightly volatile
Short Term Debt29.2 K42.2 K28.6 K
Slightly volatile
Common Stock29.2 M27.8 M7.3 M
Slightly volatile
Other Current Liabilities4.3 M4.1 M1.2 M
Slightly volatile
Property Plant And Equipment Net67.7 K46.5 K56.4 K
Pretty Stable
Non Current Assets Total225 K192.3 K135.3 K
Slightly volatile
Cash And Short Term Investments8.3 M7.9 M2.2 M
Slightly volatile
Net Receivables218.4 K208 K70.5 K
Slightly volatile
Liabilities And Stockholders Equity8.8 M8.3 M2.4 M
Slightly volatile
Common Stock Shares Outstanding5.2 M4.9 M1.1 M
Slightly volatile
Other Stockholder Equity1.9 M3.4 M1.2 M
Slightly volatile
Property Plant Equipment85.2 K59.7 K117.3 K
Slightly volatile
Capital Stock29.2 M27.8 M7.4 M
Slightly volatile
Property Plant And Equipment Gross72.2 K46.5 K136.7 K
Slightly volatile
Non Currrent Assets Other6.1 K6.5 K34 K
Pretty Stable
Other Assets16.3 K17.2 K36.4 K
Pretty Stable
Intangible Assets132.3 K108.2 K177.3 K
Slightly volatile
Short and Long Term Debt Total58 K61.1 K53.4 K
Slightly volatile
Deferred Long Term Liabilities216.4 K243.4 K265.4 K
Slightly volatile

Clearmind Medicine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.1 M3.8 M1.6 M
Slightly volatile
Total Operating Expenses6.9 M6.6 M2.6 M
Slightly volatile
Other Operating Expenses3.8 MMM
Slightly volatile
Depreciation And Amortization60.4 K46 K131.3 K
Slightly volatile
Selling And Marketing Expenses141.6 K159.3 K173.7 K
Slightly volatile

Clearmind Medicine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock60.4 K57.5 K38.9 K
Slightly volatile
Total Cash From Financing Activities7.6 M7.2 M2.5 M
Slightly volatile
End Period Cash Flow7.9 M7.6 MM
Slightly volatile
Begin Period Cash Flow6.6 M6.2 M1.5 M
Slightly volatile
Depreciation64.9 K46 K121.1 K
Slightly volatile
Change To NetincomeM2.9 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital756.3 K850.8 K927.6 K
Slightly volatile
Average Payables134.9 K128.5 K54.7 K
Slightly volatile
Capex To Depreciation0.07320.07740.4222
Slightly volatile
Payables Turnover0.05230.04570.0282
Slightly volatile
Cash Per Share2.361.452.0256
Pretty Stable
Days Payables Outstanding15 K8.3 K29.8 K
Slightly volatile
Income Quality0.951.061.0664
Slightly volatile
Intangibles To Total Assets0.01630.01720.0405
Very volatile
Net Debt To EBITDA1.221.287.3228
Slightly volatile
Current Ratio1.871.974.2657
Pretty Stable
Graham Number3.844.049.9973
Slightly volatile
Capex Per Share0.01910.02020.203
Pretty Stable
Average Receivables199 K189.5 K92.6 K
Slightly volatile
Interest Debt Per Share0.02290.02410.1303
Slightly volatile
Debt To Assets0.0080.00840.0368
Slightly volatile
Days Of Payables Outstanding15 K8.3 K29.8 K
Slightly volatile
Ebt Per Ebit0.820.70.9944
Pretty Stable
Quick Ratio1.871.974.2852
Pretty Stable
Net Income Per E B T0.830.971.0321
Slightly volatile
Cash Ratio1.741.834.0274
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.751.152.0349
Slightly volatile
Debt Ratio0.0080.00840.0368
Slightly volatile

Clearmind Medicine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.6 M5.3 M1.8 M
Slightly volatile

Clearmind Fundamental Market Drivers

Cash And Short Term Investments6.9 M

About Clearmind Medicine Financial Statements

Clearmind Medicine stakeholders use historical fundamental indicators, such as Clearmind Medicine's revenue or net income, to determine how well the company is positioned to perform in the future. Although Clearmind Medicine investors may analyze each financial statement separately, they are all interrelated. For example, changes in Clearmind Medicine's assets and liabilities are reflected in the revenues and expenses on Clearmind Medicine's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Clearmind Medicine Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue30.7 K31.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:
Check out the analysis of Clearmind Medicine Correlation against competitors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.69)
Return On Assets
(0.58)
Return On Equity
(2.68)
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.